UK +44 (0)1223 491486      USA toll free 1-866 877 2185

Qkine and Enantis sign licensing deal for hyperstable FGF2-STAB®

Qkine and Enantis have concluded a global licensing deal for Enantis’s patented FGF2-STAB® technology. FGF2-STAB® is a hyperstable form of FGF-2 (bFGF), a core reagent for stem cell culture. FGF2-STAB (FGF2-G3) does not degrade in culture media for enhanced weekend-free stem cell culture media and advanced chemically defined systems, such as those needed in the cultured meat industry.

By |2021-07-26T08:14:57+00:00July 26th, 2021|animal-free, cellular agriculture, news, press release, protein engineering, protein science, stem cells|Comments Off on Qkine and Enantis sign licensing deal for hyperstable FGF2-STAB®

Rob Nixon joins Qkine as Head of Commercial and Dr Cassie Doherty is appointed to the board

Cambridge, UK 21 July 2020: Qkine – a specialist developer and manufacturer of proteins for stem cell, organoid and regenerative medicine applications – is delighted to announce the appointment of Rob Nixon to its management team as Head of Commercial and Dr Cassie Doherty, Investment Director at Parkwalk, to its board. With years of [...]

By |2020-12-08T16:06:23+00:00July 21st, 2020|news, press release|Comments Off on Rob Nixon joins Qkine as Head of Commercial and Dr Cassie Doherty is appointed to the board

Qkine secures £1.5M series A funding from leading life science investors

Cambridge, UK 08 June 2020: Qkine – a specialist developer and manufacturer of proteins for stem cell, organoid and regenerative medicine applications – today announced the successful closure of a £1.5M series A investment round to accelerate the global scale-up of its commercial operations and make key hires to its leadership team. The funding [...]

By |2020-12-08T16:09:36+00:00June 8th, 2020|news, press release|Comments Off on Qkine secures £1.5M series A funding from leading life science investors

Qkine secures additional £550K to extend development of R&D pipeline and accelerate commercialisation of product portfolio

Cambridge, UK 03 June 2019: Qkine, specialist manufacturer of proteins for stem cell, organoid and regenerative medicine applications, has closed a further round of investment. The £550K funding round was led by Cambridge Enterprise and five angel investors – all of whom followed initial seed investments made in April 2018. Joining the original investors [...]

By |2020-08-25T09:06:13+00:00June 3rd, 2019|news, press release|Comments Off on Qkine secures additional £550K to extend development of R&D pipeline and accelerate commercialisation of product portfolio

Qkine backed by Cambridge Enterprise and a quintet of angels

University of Cambridge spin-out Qkine has closed its seed investment round supported by Cambridge Enterprise, the commercialisation arm of the University, and a team of five angels led by Jim Warwick. The amount is undisclosed. Qkine is a specialist manufacturer of proteins that are used for control of stem cell growth and differentiation. The [...]

By |2020-08-25T10:00:53+00:00April 23rd, 2018|news, press release|Comments Off on Qkine backed by Cambridge Enterprise and a quintet of angels

Go to Top